Medication therapy works best when it’s paired with ongoing lifestyle support in obesity care – especially when we’re talking about GLP‑1s. The Omada Insights Lab evaluated outcomes in the Enhanced GLP-1 Care Track at one year, and found...
Eli Lilly has announced a major policy change for participants in the 340B Drug Pricing Program, effective February 1, 2026. Moving forward, covered entities will be required to submit claims data for all Lilly drugs dispensed through in‑house pharmacies...
On December 19, 2025, President Trump announced new Most-Favored-Nation (MFN) drug pricing agreements with nine additional major pharmaceutical manufacturers, these include GSK, Sanofi, Genentech, Amgen, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Novartis, Gilead and Merck. These agreements aim to...
Major changes will impact healthcare and drug pricing in 2026 – from new federal pricing policies and regulations to a surge of high-impact drug launches. At ProAct, we’re already preparing...
On December 22nd, the Food and Drug Administration (FDA) approved Novo Nordisk’s oral semaglutide tablet, a 25 mg dose of the same active ingredient found in injectable Wegovy and Ozempic. Marketed under the brand name Wegovy, the tablet...
